Jieli

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jieli

Property Description
Active ingredient Tinidazole
Form Tablet, Oral Suspension
Pharmacological class Nitroimidazole Antimicrobial
Common use To resolve microbial and parasitic infections
Origin Synthetic

Jieli is a synthetic oral medication containing the single active ingredient Tinidazole, an agent primarily used to combat infections caused by certain microbial and parasitic pathogens. It is formally classified as a 5-nitroimidazole derivative belonging to the nitroimidazole antimicrobial class, which is clinically recognized as a highly effective anti-infective agent. This compound represents a later-generation development that is often used as a preferred alternative to related compounds due to distinct pharmacokinetic properties.

Composition and Available Forms of Jieli

The exclusive therapeutic component of Jieli is Tinidazole, which is formulated with necessary inactive excipients to ensure stable and effective drug delivery. The product is administered via the oral route and is available in two principal dosage forms: a solid tablet and a liquid oral suspension. The availability of the oral suspension form provides a crucial alternative for pediatric patients and others who may require an option other than swallowing a solid medication, enhancing the drug's applicability across patient groups.

General Purpose of This Anti-infective Agent

The primary purpose of Jieli is to resolve underlying infections by functioning as a targeted anti-infective agent. It is designed to selectively target and eliminate susceptible strains of microorganisms, specifically obligate anaerobic bacteria and certain protozoa (single-celled parasites). The medicine achieves its effect by becoming chemically activated only inside these pathogenic cells, a process that leads to fundamental and irreversible damage to their DNA, preventing their growth and reproduction and thereby eliminating the source of the infection. A typical neutral use scenario for this class of medicine involves treating infections caused by parasites that are resistant to other common antimicrobials.

What side effects are possible with Jieli?

Possible Side Effects and Safety Information

The safety profile of Jieli (Tinidazole) is formally classified by health authorities based on the frequency and system-organ class of reported reactions.

Adverse Reaction Scope

The most commonly reported adverse reactions (ge 1%) are related to the Gastrointestinal and Nervous Systems. These common effects include metallic or bitter taste, nausea, vomiting, headache, and dizziness.

Serious adverse reactions are reported in official labeling, primarily affecting the Nervous System. These include the potential for convulsions and peripheral neuropathy (tingling or numbness in the limbs). The development of peripheral neuropathy is specifically associated with prolonged or repeated courses of treatment. Rare reports of severe mucocutaneous reactions (like Stevens-Johnson syndrome) and acute hypersensitivity reactions have also been documented.

Safety Constraints and Special Populations

Official labeling imposes specific safety constraints:

  • Alcohol Restriction: The consumption of alcoholic beverages must be strictly avoided during therapy and for at least 72 hours after the last dose due to the risk of a severe disulfiram-like reaction (e.g., flushing, vomiting, abdominal cramps).
  • Pregnancy: The medication is contraindicated during the first trimester of pregnancy. Use during later trimesters requires specific risk assessment.
  • Lactation: Nursing should be suspended for at least 72 hours following the final dose to minimize infant exposure.
  • Pre-existing Conditions: Caution is advised in patients with a history of blood disorders (due to transient leukopenia) or pre-existing organic neurological diseases.

The safety documentation thus defines a risk profile characterized by high-frequency, non-serious gastrointestinal effects, balanced against low-frequency, clinically significant neurological and hypersensitivity risks that warrant specific attention under regulatory guidelines.

Overdose and Emergency Response

The official regulatory profile for Jieli overdosage is defined by a need for immediate action, as reports of human overdose are anecdotal and no consistent data is documented regarding specific clinical signs or symptoms of acute overexposure. A suspected overdose requires that immediate medical attention be sought, and it is required to contact a Poison Help line.

The primary concern in overexposure is the potential for exacerbation of severe neurological adverse effects associated with the drug class. These serious outcomes include convulsive seizures and peripheral neuropathy, which may manifest as numbness or a pins-and-needles sensation. If an individual experiences a seizure, has trouble breathing, or becomes unresponsive/collapsed due to suspected overdosage, emergency medical services must be contacted immediately.

No specific antidote is known for Tinidazole overdosage, and management is mandated to be symptomatic and supportive treatment. Clinical observation requires close monitoring for abnormal neurological signs. The official drug label documents that the procedure of hemodialysis is an effective supportive measure. Tinidazole is easily dialyzable, with approximately 43% of the compound eliminated during a six-hour session, significantly increasing the drug's clearance in these situations.

Therapeutic Uses of Jieli

Jieli (Tinidazole) is generally used across therapeutic domains where infections are caused by specific protozoa and obligate anaerobic bacteria. The medication is applied in clinical settings marked by disruptive symptom manifestations, providing support that helps ease the overall symptom burden.

This drug is commonly used across conditions presenting with acute episodes, including the treatment of parasitic infections such as Giardiasis and Amebiasis (intestinal forms and liver abscess), as well as bacterial conditions like Bacterial Vaginosis and the parasitic STD Trichomoniasis. It helps address symptom clusters that may become intense or disruptive, particularly those related to gastrointestinal discomfort and urogenital discharge and odor. Treatment provides support that contributes to improved comfort during periods of heightened symptoms for patients, including pediatric patients over the age of three.

Quick Fact: Therapeutic Support for Infection Symptoms

The medication may also be part of symptomatic management in strategic clinical settings to help reduce the risk of postoperative anaerobic infections. Jieli assists with maintaining functional stability by contributing to easing acute symptoms such as painful abdominal cramps and disruptive abnormal discharge.

Regulatory References

  1. NIH DailyMed label for Tinidazole

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Jieli — Official Regulatory Information

The eligibility profile for Jieli (Tinidazole) is strictly defined by governmental health authorities based on age, physiological status, and underlying medical conditions.


Eligibility scope

Classification Population Rule (Official Regulatory Status)
Populations for whom use is allowed Adults; Pediatric patients older than three years of age (> 3 years) for Giardiasis and Amebiasis; Non-pregnant adult women for Bacterial Vaginosis.
Populations for whom use is not recommended Women in the second and third trimesters of pregnancy (unless benefit outweighs risk); Patients with severe hepatic impairment; Children under three years of age.
Populations for whom use is contraindicated Patients with a history of hypersensitivity to Jieli or other nitroimidazole derivatives; Women in the first trimester of pregnancy; Nursing mothers; Patients with organic neurological disorders; Patients with a history of blood dyscrasias.

Age-related eligibility rules: Jieli is approved for adults. Its use in pediatric patients is restricted to those older than three years of age for specific protozoal infections. Safety and effectiveness are not established for children under three years of age.

Pregnancy and lactation eligibility status: Use is contraindicated during the first trimester of pregnancy and is generally not recommended thereafter unless strictly necessary. The medicine is contraindicated for nursing mothers; breastfeeding must be interrupted for at least 72 hours following the final dose.

Condition-specific eligibility rules: Contraindications include a history of hypersensitivity, organic neurological disorders, and blood dyscrasias. Use is not recommended for patients with severe hepatic impairment. Use requires caution in patients with a history of seizures or other central nervous system conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Jieli details specific drug-drug, food, and product interactions that are established by governmental health agencies. The interaction profile is structured around pharmacokinetic and pharmacodynamic risks, which dictate necessary usage constraints.

Exposure-Altering Combinations (Pharmacokinetic)

Substance Category Interaction Consequence Status
Strong CYP Inhibitors Increased Jieli exposure Use with caution; may require specific monitoring
Strong CYP Inducers Decreased Jieli exposure Avoid co-administration due to reduced efficacy
Transporter Modulators (e.g., P-gp) Altered Jieli plasma levels Requires case-by-case assessment

Pharmacodynamic Risk Combinations

Co-administration with other medicinal products known to share a specific pharmacological effect, such as QTc interval prolongation or CNS depression, is associated with an additive risk of the shared effect. This requires careful consideration if the combination is deemed necessary.

Non-Medicinal Interactions

Interactions with non-medicinal products, such as specific herbal supplements (e.g., St. John's Wort) or certain foods (e.g., grapefruit juice), are documented to alter Jieli's systemic exposure. Specific statements may mandate time separation requirements from antacids or other oral supplements to maintain drug absorption.

Interaction Constraints

Jieli's official labeling identifies certain combinations as contraindicated, meaning co-administration is strictly forbidden due to unacceptable risk. Other interactions require management, which involves heightened patient monitoring or the implementation of specific constraints to mitigate the documented risk.

Mechanism of Action

Selective Prodrug Activation

Jieli is a prodrug that remains inert until it diffuses into the target pathogen's cell, where it encounters specialized nitroreductase enzymes and low-redox potential ferredoxin proteins. This enzymatic interaction initiates a reduction process, generating highly reactive intermediate compounds. This requirement for specific microbial enzymes ensures a high degree of selective toxicity, concentrating the drug's action on the target cells.


Irreversible DNA Damage Cascade

The activated compounds are nitro radical anions that act as molecular toxins. These radicals immediately attack the pathogen's fundamental DNA structure, causing irreversible strand breaks and structural destabilization. This damage cascade abruptly halts the microbe's essential processes—namely, replication and transcription—leading to rapid cell death and the necessary reduction of the microbial population.


Mechanistic Constraint to Anaerobic Systems

This molecular mechanism is strictly dependent on an anaerobic environment to function. The presence of oxygen rapidly neutralizes the toxic radical intermediates, rendering the drug ineffective against aerobic organisms. This biological constraint dictates the drug’s limited spectrum of activity, explaining why it only engages the biological systems of obligate anaerobes and certain protozoa.

Dosage and Administration Information

How to Use Jieli

The administration of Jieli (Tinidazole) is strictly defined by short-course, high-dose protocols detailed in official prescribing information. The medication is designed for oral administration and must always be taken with food—either during or immediately after a meal—to ensure proper use. The drug is available as 250 mg and 500 mg tablets, and an oral suspension can be prepared from the tablets for patients who cannot swallow solid forms.


Official Dosing and Duration

The dosing schedule is fixed based on the infection being treated. Standard adult regimens typically involve a single, one-time dose or a once daily schedule for a very brief duration, ranging from one to five days.

Indication Standard Adult Regimen Total Duration
Trichomoniasis Single 2 g dose 1 day
Intestinal Amebiasis 2 g once daily 3 days
Amebic Liver Abscess 2 g once daily 3 to 5 days

Administration Contexts

Jieli is approved for use in pediatric patients older than three years for certain parasitic infections. The dosage in this population is weight-based, using 50 mg/kg up to a maximum of 2 g per dose.

Two critical procedural conditions govern its use:

  • Partner Treatment: For the indication of Trichomoniasis, simultaneous treatment of sexual partner(s) is mandatory to prevent re-infection.
  • Renal Impairment: While no dose adjustment is generally necessary for impaired kidney function, patients undergoing hemodialysis require an additional half-dose administered after the dialysis session is complete.

These instructions collectively establish the specific administrative context and duration required for standardized treatment protocols.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Jieli

The clinical evaluation of Jieli (Tinidazole) has focused on exploring its use in treating specific parasitic and bacterial infections. The research evidence primarily consists of comparative trials, including Randomized Controlled Trials (RCTs), along with systematic reviews and meta-analyses, which provide context regarding what has been observed in study populations. Findings from these sources help illustrate patterns of symptom evolution and organism clearance over defined time intervals.


Evidence for Use in Trichomoniasis

Research examining Jieli for Trichomoniasis (an infection caused by the Trichomonas vaginalis parasite) includes comparative studies, often exploring different single-dose regimens. Studies documented the clearance of the T. vaginalis parasite in the observed populations following the compound's administration. Some research has explored the compound's use in patients with infections that were unresponsive to previous conventional therapies, though evidence in this specific situation remains limited to smaller studies.


Evidence for Use in Giardiasis

The research supporting the use of Jieli for Giardiasis includes multiple RCTs, comparative trials, and systematic reviews. The core research focus was the parasitological cure rate (confirming the absence of the parasite in stool samples) and the resolution of common gastrointestinal symptoms. Studies monitored the clearance of the Giardia parasite in observed populations following administration. However, some aggregated data reviews have noted statistical variation, known as heterogeneity, when combining results from multiple different trials.


Evidence for Use in Bacterial Vaginosis (BV)

The evidence for Jieli in treating Bacterial Vaginosis (BV) includes Placebo-Controlled Trials and comparative studies. Researchers monitored clinical cure (defined by specific diagnostic criteria) and the rate at which the infection returned (recurrence) during follow-up. Clinical trials reported measurements of clinical cure (resolution of signs and symptoms) at defined short-term follow-up points, compared to a placebo. A consistent finding across all treatments for BV, including Jieli, is the challenge of high recurrence rates, which remains an area where long-term data is sought.


What Is Still Uncertain or Under Research

Long-term outcomes—meaning extended periods of stability or recurrence—are not fully established in the available regulatory summaries, as most trials were designed for short-to-intermediate time intervals. Data for certain groups, such as those with specific comorbidities or varying infection severities, remains insufficient in the main evidence base, meaning subgroup findings are uncertain.

Key Studies & References

  1. Comparative efficacy of drugs for treating giardiasis: a systematic update of the literature and network meta-analysis of random

Frequently Asked Questions (FAQ)

Common questions about Jieli (FAQ)


Q: Why did my doctor prescribe Jieli instead of another treatment?

A: Official documents indicate that the active ingredient in Jieli has a longer half-life (a measure of how long it stays in the body) compared to similar medications. This longer half-life allows for less frequent dosing and may be a factor in selecting Jieli for certain short-course treatments.


Q: How long do the effects of Jieli typically last?

A: According to official product information, the active ingredient in Jieli has a plasma elimination half-life that ranges between 12 and 14 hours. This half-life indicates how quickly the drug is processed by the body.


Q: Does Jieli cause drowsiness or fatigue?

A: Studies and official information indicate that common adverse reactions may include symptoms of the nervous system, such as dizziness. Patients have also reported generalized weakness or fatigue, which were reported as common occurrences in clinical trials.


Q: Can I take Jieli with aspirin or ibuprofen?

A: Jieli may slow down the rate at which certain other medications, including some anti-inflammatory drugs, are removed from the body. This potential interaction could lead to higher levels of the co-administered drug in your system. Official documentation notes that this potential interaction should be considered when Jieli is taken alongside other medications.


Q: Can Jieli be taken with supplements or vitamins?

A: Regulatory documents advise that certain vitamins, supplements, or oral preparations can alter how the body absorbs or processes Jieli. Specific statements often require time separation from antacids or other oral supplements to ensure proper absorption and maintain drug levels.


Q: Does Jieli require special monitoring or blood tests?

A: Official labeling advises caution in patients with a history of blood disorders because Jieli can potentially cause temporary changes in white blood cell counts, known as transient leukopenia or neutropenia. For patients with certain risk factors, monitoring, which may include blood tests, can be discussed with a healthcare provider.


Q: How long were the main clinical trials for Jieli?

A: Research evidence for Jieli is based on clinical trials that used a range of timeframes, typically reflecting the short treatment courses prescribed. For instance, studies included single-dose regimens, 3-day courses, and 5-day daily courses, with follow-up periods that could extend for several months.


Q: Can Jieli be crushed or split?

A: According to official dosage information, the tablets may be crushed or pulverized by a pharmacist or healthcare provider to prepare an oral suspension. This method is noted for patients who may have difficulty swallowing the tablet form.


Q: Why do some people report feeling no effect from Jieli?

A: The drug is designed with a selective mechanism, meaning it only activates when it encounters specific enzymes within the target pathogen and requires an anaerobic (low oxygen) environment. If the organism causing the infection is resistant to this process, the medication may not be effective.


Q: Are there any studies on Jieli's effectiveness in diverse populations?

A: The official label provides information on effectiveness and safety based on the populations who were included in the primary clinical trials. Information regarding these diversity factors is generally included in the overall safety and efficacy review, but separate discussions are usually only provided if a difference in response was clearly observed.


Q: How quickly can I expect Jieli to start working?

A: Studies show that the active ingredient in Jieli reaches its highest concentration in the bloodstream approximately 1 to 2 hours after the dose is taken. This measurement indicates when the drug is maximally present in your system.


Q: What happens if I stop taking Jieli suddenly?

A: Regulatory patient counseling indicates the importance of completing the full prescribed course of treatment, even if symptoms improve early. Stopping the medication too soon may cause the infection to return. Official documentation does not indicate any known withdrawal symptoms associated with suddenly stopping Jieli.


Q: Can Jieli affect my sleep pattern?

A: Adverse reaction reports have included insomnia (trouble sleeping) and other mood or mental changes, which are types of side effects that may potentially affect sleep patterns.


Q: Are there special warnings for elderly patients using Jieli?

A: Clinical research has not identified specific age-related problems in the elderly population that would restrict the use of Jieli. However, official guidance notes that dose adjustments might be necessary for older patients if they have underlying age-related issues with their organ function.


Q: Is Jieli available over the counter?

A: Official regulatory documentation states that Jieli is a prescription-only medication. As a prescription drug, it requires dispensing and authorization from a licensed healthcare provider.


Q: What does 'contraindication' mean in the context of Jieli?

A: A contraindication is a regulatory term that means the medication must not be used in certain situations because the risks are deemed medically unacceptable. Examples for Jieli include the first trimester of pregnancy and patients with a history of a severe allergic reaction (hypersensitivity) to the drug.


Q: Is Jieli known to cause weight gain or weight loss?

A: Official reports indicate that a common metabolic side effect is anorexia (decreased appetite), and weight loss has been reported as a less common reaction. Weight gain is not explicitly listed among the common adverse reactions documented for Jieli.


Q: What should I do if I miss a dose of Jieli?

A: General patient information indicates that if a dose is missed, it can be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped to prevent taking too much medication. Taking double or extra doses to compensate for a missed dose is not advised.


Q: Is it true that Jieli has a Black Box Warning?

A: Official labeling includes a serious warning within its Warnings and Precautions section concerning the potential for genetic toxicity and carcinogenicity (cancer-causing risk), which has been observed with a chemically related drug. Regulatory authorities require that Jieli only be used for its approved indications as a safety constraint.


Q: Does Jieli contain gluten, lactose, or other common allergens?

A: The official label details the list of inactive ingredients (excipients) used in the product. Patients with known allergies or sensitivities can review the complete list of inactive ingredients on the product label with a healthcare professional.


Q: Is there a generic version of Jieli available?

A: Jieli is a brand name. The active ingredient in this medication is Tinidazole, which is the generic name for the drug. Generic versions of Tinidazole may be available following regulatory approvals and patent expiration of the brand-name product.


Q: Can Jieli be used to prevent a condition?

A: Official regulatory indications specify that Jieli is approved for the treatment of infections that have already been diagnosed, such as Giardiasis and Bacterial Vaginosis. The medication is not generally approved or intended for the prevention (prophylaxis) of these conditions.


Q: Does the time of day matter when taking Jieli?

A: The official dosing instructions state that the medication should be taken 'once daily' and must always be taken with food. However, the regulatory information does not mandate a specific time of day, such as morning or evening, for the dose to be effective.

How should Jieli be stored and disposed of?

Jieli should be stored precisely according to the instructions provided with the original packaging. Typically, most medicines require storage in a cool, dry place, protected from direct sunlight and humidity. It is crucial to keep the medication in its original container and ensure it is kept out of sight and reach of children and pets to prevent accidental ingestion or misuse. Do not use Jieli beyond its expiration date.

Safe Disposal

The most recommended method for disposing of unused or expired Jieli is through a drug take-back program. Many local pharmacies, law enforcement agencies, or community collection events provide authorized drop-off locations for pharmaceuticals.

If a take-back option is not readily available, most medicines that are not on a specific 'flush list' should be disposed of in the household trash. To do this, mix the medicine (without crushing tablets or capsules) with an unappealing substance like used coffee grounds or cat litter, place the mixture in a sealed plastic bag, and then discard it in the trash. Always scratch out personal information from the prescription label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Jieli found in:

A-Z Index: